The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health
The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health in Patients With Prediabetes and Type 2 Diabetes: a Randomsied, Double-blinded, Placebo-controlled Trial
Sponsor: Monash University
Listed as NCT02917928, this PHASE2 trial focuses on Cardiovascular Risk Factors and Cognitive Function 1, Social and remains ongoing. Sponsored by Monash University, it has been updated 9 times since 2016, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Jul 2022 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jan 2021 — Jul 2022 [monthly]
Unknown Status PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Sep 2018 — Sep 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Monash University
For direct contact, visit the study record on ClinicalTrials.gov .